Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro microbiology and mouse tumor model
PubMed 12032331 · doi:10.1073/pnas.112203099
What was done
Researchers evaluated the antibacterial effects of sulforaphane in vitro against 3 reference strains and 45 clinical isolates of Helicobacter pylori, including antibiotic-resistant strains, as well as intracellular bacteria inside human epithelial cells (HEp-2). In parallel, they tested whether sulforaphane prevented benzo[a]pyrene-induced forestomach tumors in wild-type ICR mice and nrf2-knockout mice to determine the role of phase 2 detoxication enzymes.
What was found
Sulforaphane acted as a bacteriostatic agent against all 48 tested strains, with a minimum inhibitory concentration for 90% of strains (MIC90) of 4 μg/ml or less, regardless of conventional antibiotic resistance. Brief exposure was bactericidal and eradicated intracellular H. pylori from HEp-2 epithelial cells. In mice, sulforaphane prevented benzo[a]pyrene-induced forestomach tumors, an effect that was completely abolished in mice lacking the nrf2 gene.
Why it matters
These findings suggest sulforaphane has dual protective mechanisms against gastric carcinogenesis by inhibiting H. pylori infection (even in antibiotic-resistant or intracellular reservoirs) and stimulating chemoprotective phase 2 detoxication pathways.
Limits
The study is limited to in vitro cell cultures and mouse models; no human clinical trials or pharmacokinetic data were included. Specific animal sample sizes, exact tumor reduction percentages, and in vivo efficacy against active gastric H. pylori colonisation were not quantified in the abstract.
Cited by
- supports In vitro studies published around 2002 demonstrated that sulforaphane kills natural and doubly antibiotic-resistant clinical strains of Helicobacter pylori.